PTGX

121.4002.11%
VT

Venkat Thalladi

EVP & Chief Technical Officer

Mr. Venkat Thalladi, PhD, serves as EVP & Chief Technical Officer of Protagonist Therapeutics, Inc. from April 2026. Mr. Thalladi joined the Protagonist Therapeutics, Inc. in April 2026. Mr. Thalladi is Senior Vice President of Chemistry, Manufacturing & Controls at DiCE Molecules SV Inc. and DICE Therapeutics, Inc. since June 2021. Prior to DiCE, he was at Theravance Biopharma, most recently serving as the Vice President and Head of Pharmaceutical Development. At Theravance, he contributed to 15 research and development programs ranging from preclinical to Phase 3 clinical products as well as the marketed products YUPELRI® and VIBATIV®. He led multiple drug product development programs at Theravance, most recently ampreloxitine for symptomatic neurogenic orthostatic hypotension, izencitinib for ulcerative colitis and Crohn’s disease, nezulcitinib for COVID-19, TD-8236 for asthma and TD-1058 for idiopathic pulmonary fibrosis. These programs included tablets for oral delivery to nebulized solutions and inhaled dry powders for lung delivery. He ushered in new drug delivery technologies at Theravance, leading the efforts in an ocular program to develop products that last in the eye for several months and a topical program that resulted in partnership with Pfizer. Prior to Theravance, he was at XenoPort as a Principal Investigator in the formulation development group and at Worcester Polytechnic Institute as an Assistant Professor in the Department of Chemistry and Biochemistry. He received his PhD in Chemistry from the University of Hyderabad and conducted post-doctoral work at the University of Essen and Harvard University.

Positions